GVR Report cover Cell Therapy Raw Materials Market Size, Share & Trends Report

Cell Therapy Raw Materials Market Size, Share & Trends Analysis Report By Product (Media, Sera), By End-use (Biopharmaceutical & Pharmaceutical Companies, CROs & CMOs), By Region, And Segment Forecasts, 2023 - 2030

  • Report ID: GVR-4-68040-137-9
  • Number of Report Pages: 130
  • Format: PDF, Horizon Databook
  • Historical Range: 2018 - 2021
  • Forecast Period: 2023 - 2030 
  • Industry: Healthcare

Cell Therapy Raw Materials Market Trends

The global cell therapy raw materials market size was estimated at USD 3.46 billion in 2022 and is expected to grow at a compound annual growth rate (CAGR) of 24.47% from 2023 to 2030. Innovation in cell culture products including media and sera, and the increasing prevalence of chronic diseases such as cancer, diabetes, and autoimmune disorders are expected to drive the market growth over the forecast period. Cell therapy holds immense potential in treating these conditions, and as a result, there is a growing demand for raw materials required in the production of cell-based therapies thereby fueling the market growth.

U.s. Cell Therapy Raw Materials market size and growth rate, 2023 - 2030

The COVID-19 pandemic had a significant impact on the market. The outbreak disrupted supply chains and manufacturing processes, leading to shortages and delays in the production of cell-based therapies. Lockdowns and travel restrictions hindered the transportation of raw materials, causing disruptions in the availability of critical components. Moreover, many research and clinical trials related to cell therapies were temporarily halted or slowed down due to the diversion of resources toward pandemic response efforts. Despite these challenges, the pandemic also underscored the importance of cell-based therapies, leading to increased investments in the sector and accelerated regulatory approvals for some treatments. Overall, the market has faced both setbacks and opportunities in the wake of COVID-19, and its trajectory continues to be shaped by ongoing global health developments.

Increasing investments and funding in cell therapies targeting various diseases including cancer, urinary problems, and others are likely to drive the market growth over the forecast period. For instance, in August 2023, NK: IO Limited raised USD 3.50 million (Euro 3.2 million) for cell therapy targeting the treatment of solid tumors. As more companies like NK: IO pursue research and development in this area, the demand for raw materials essential for the production of cell therapies is expected to surge. Raw materials such as cell culture, media, sera, and supplements are integral components of cell therapy manufacturing. These materials are needed to cultivate and expand therapeutic cells effectively before they can be administered to patients.

The advancements in biotechnology and cell culture techniques such as three-dimensional cell culture, aseptic techniques, and cell preservation have played a pivotal role in boosting the market. These innovations have led to the development of more efficient and cost-effective manufacturing processes, which have reduced the overall production costs of cell therapies. Consequently, this has made cell-based treatments more accessible to a wider patient population, driving up the demand for raw materials.

The increasing number of clinical trials for cell therapy would likely offer profitable opportunities to the market, as these demand raw materials for the successful launch of the trials. Several research institutes and biopharmaceutical & pharmaceutical companies are working on cell therapy development. For instance, in August 2023, UCART22, UCART123, and UCART20x22 are the three chimeric antigen receptor (CAR) T-cell treatments that Cellectis is now testing in three clinical trials: NATHALI-01, BALLI-01, and AMELI-01.

Regulatory agencies have been actively supporting the growth of the cell therapy industry by streamlining approval processes and providing clear guidelines. For instance, in March 2022, the U.S. FDA released two new draught guideline materials to aid sponsors who are creating cell and gene therapy (CGT) products. The first, Human Gene Therapy Products Incorporating Human Genome Editing, offers suggestions on details, such as safety, study design, and manufacturing, that should be included in IND submissions for these medicines. The second draft includes the considerations for the development of CAR-T Cell products. The FDA noted that although the title expressly mentions CAR-T cell therapies, which are intended to treat cancer, these regulations also apply more to other gene-edited cell treatments, such as T cell receptor (TCR) and natural killer (NK) cell therapies. On safety, clinical study, design, manufacturing, and analytical comparability of CAR-T products are all addressed in the publication. This has instilled confidence among investors and manufacturers, encouraging them to invest in research and development activities. As a result, the market for cell therapy raw materials has expanded to meet the growing needs of the industry.

Product Insights

Based on product, the market is segmented into media, sera, cell culture supplements, antibodies, reagents & buffers, and others. The media segment held the largest market share of 24.20% in 2022. This is attributed to advancements in cell therapy research and development that have driven the need for specialized media products that support the growth and expansion of therapeutic cells. Moreover, the increasing product development of media for stem cell-based therapy would likely drive the segment growth over the coming years. For instance, in September 2021, Bio-Techne introduced a novel medium for the development and preservation of induced pluripotent stem cells (iPSCs) for use in both clinical and translational operations.

The antibodies segment is anticipated to grow at the fastest CAGR of 27.55% from 2023 to 2030. Antibodies play a pivotal role in cell-based therapies as they are essential components for targeted treatments and immune modulation. The increasing prevalence of cancer, autoimmune disorders, and infectious diseases has fueled the demand for antibodies in cell therapy. In addition, advancements in biotechnology and recombinant DNA technology have streamlined the production of antibodies, making them more accessible and cost-effective. Therefore, the antibodies product segment is poised for continued growth over the forecast period.

End-use Insights

Based on the end-use, the market is segmented into biopharmaceutical & pharmaceutical companies, CMOs & CROs, and others. The biopharmaceutical & pharmaceutical companies segment held the largest market share of 53.70% in 2022. These sectors have increasingly recognized the immense potential of cell therapies in revolutionizing healthcare by providing novel treatments for a wide range of diseases, including cancer, autoimmune disorders, and degenerative conditions.

Global Cell Therapy Raw Materials market share and size, 2022

As a result, investments have been significantly ramped up in research, development, and commercialization of cell-based therapies, spurring the demand for high-quality raw materials essential for cell therapy production. For instance, in September 2023, Novo Nordisk A/S announced an investment of USD 136 million for the construction of a cell therapy manufacturing facility at Cellerator in Denmark. The manufacturing facility, which will be housed at the Technical University of Denmark (DTU), will produce cell therapies, particularly stem cell therapies, for use in preliminary clinical studies.

On the other hand, the CMOs & CROs segment is anticipated to register the fastest CAGR of 25.18% over the forecast period. The escalating trend of outsourcing services to CROs and CMOs has significantly propelled the growth of this end-user segment in the market. As the field of cell therapy continues to advance and gain prominence in the healthcare industry, biopharmaceutical companies are increasingly seeking specialized expertise and resources to streamline their production processes. CROs and CMOs offer a comprehensive range of services, from research and development to manufacturing, allowing these companies to focus on their core competencies while minimizing operational costs and risks. This strategic shift towards outsourcing has created a surge in demand for raw materials essential for cell therapy production, including growth factors, and culture media, among others by CMOs, & CROs, thereby fostering the expansion of the market. Moreover, as the biopharmaceutical industry continues to invest in cell therapy research and development, the demand for raw materials will persistently rise, benefiting both CMOs and CROs as key contributors to advancements in this promising field.

Regional Insights

North America dominated the market with a share of 45.98% in 2022. This is attributed to the increasing prevalence of chronic diseases such as cancer, diabetes, and cardiovascular disorders which has led to a growing demand for innovative cell-based therapies. These therapies offer promising treatment options that can potentially address the unmet medical needs of patients, spurring the demand for raw materials. Furthermore, the region's robust healthcare infrastructure and well-established regulatory framework have created a conducive environment for the development and commercialization of cell therapies. This has attracted investments from both government agencies and private companies, fueling research and development activities in the field.

Cell Therapy Raw Materials Market Trends, by Region, 2023 - 2030

Asia Pacific is anticipated to witness the fastest CAGR of 24.96% over the forecast period. The increasing prevalence of chronic diseases and degenerative disorders in the region has spurred the demand for innovative cell therapies. These therapies offer promising solutions for conditions such as cancer, cardiovascular diseases, and neurological disorders, thereby fueling the need for raw materials in their production. Moreover, the supportive regulatory environment in many Asia Pacific countries including China and India has also been instrumental in fostering the growth of the market.

Key Companies & Market Share Insights

The key participants in the cell therapy raw materials business are implementing various strategic initiatives including partnership and collaborations to retain their market presence. For instance, in June 2023, StemCyte signed a collaboration agreement with a state-of-the-art US immune cell therapy business, to provide raw materials for drug preparation in allogeneic modified cell therapy. Moreover, in June 2023, FUJIFILM Corporation launched a human iPSC-derived iCell Blood-Brain Barrier Isogenic Kit. The kit replicates the human barrier between the blood and the brain and can help with drug discovery, medication development, and the study of diseases of the central nervous system.

In addition, several players are expanding their global footprint by establishing manufacturing facilities and distribution networks in key regions. This enables them to better serve their customers and respond to the growing demand for cell therapy raw materials on a global scale. For instance, in June 2022, OrganaBio opened a new manufacturing facility for good manufacturing practices. The facility serves as the central hub for manufacturing an extensive portfolio of perinatal and adult blood-derived tissue and cells, reinforcing the company's dedication to delivering high-quality solutions for the cell therapy industry. Some prominent players in the global cell therapy raw materials market include:

  • Thermo Fisher Scientific Inc.

  • Merck KGaA

  • Danaher

  • Sartorius Stedim Biotech

  • Actylis.

  • ACROBiosystems

  • STEMCELL Technologies.

  • Grifols, S.A.

  • Charles River Laboratories

  • RoosterBio, Inc.

  • PromoCell GmbH

Cell Therapy Raw Materials Market Report Scope

Report Attribute


Market size value in 2023

USD 4.27 billion

Revenue forecast in 2030

USD 19.77 billion

Growth rate

CAGR of 24.47% from 2023 to 2030

Base year for estimation


Historical data

2018 - 2021

Forecast period

2023 - 2030

Quantitative units

Revenue in USD million/billion, CAGR from 2023 to 2030

Report coverage

Revenue forecast, company ranking, competitive landscape, growth factors, and trends

Segments covered

Product, end-use, region

Regional scope

North America; Europe; Asia Pacific; Latin America; MEA

Country scope

U.S.; Canada; Germany; U.K.; France; Italy; Spain; Denmark; Sweden; Norway; China; Japan; India; South Korea; Australia; Thailand; Brazil; Mexico; Argentina; South Africa; Saudi Arabia; UAE; Kuwait

Key companies profiled

Thermo Fisher Scientific Inc.; Merck KGaA; Danaher; Sartorius Stedim Biotech; Actylis.; ACROBiosystems; STEMCELL Technologies; Grifols, S.A.; Charles River Laboratories; RoosterBio, Inc.; PromoCell GmbH

Customization scope

Free report customization (equivalent to up to 8 analyst’s working days) with purchase. Addition or alteration to country, regional & segment scope.

Pricing and purchase options

Avail customized purchase options to meet your exact research needs. Explore purchase options



Global Cell Therapy Raw Materials Market Segmentation

This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2018 to 2030. For this report, Grand View Research has segmented the global cell therapy raw materials market report based on product, end-use, and region:

Global Cell Therapy Raw Materials Market Report Segmentation

  • Product Outlook (Revenue, USD Million, 2018 - 2030)

    • Media

    • Sera

    • Cell Culture Supplements

    • Antibodies

    • Reagents & Buffers

    • Others

  • End-use Outlook (Revenue, USD Million, 2018 - 2030)

    • Biopharmaceutical & Pharmaceutical Companies

    • CROs & CMOs

    • Others

  • Regional Outlook (Revenue, USD Million, 2018 - 2030)

    • North America

      • U.S.

      • Canada

    • Europe

      • Germany

      • U.K.

      • France

      • Italy

      • Spain

      • Denmark

      • Sweden

      • Norway

    • Asia Pacific

      • China

      • India

      • Japan

      • South Korea

      • Australia

      • Thailand

    • Latin America

      • Brazil

      • Mexico

      • Argentina

    • Middle East and Africa (MEA)

      • South Africa

      • Saudi Arabia

      • UAE

      • Kuwait

Frequently Asked Questions About This Report

gvr icn


gvr icn

This FREE sample includes data points, ranging from trend analyses to estimates and forecasts. See for yourself.

gvr icn


We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now

Certified Icon

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.